Merck KGaA MRK.DE
What does Merck KGaA do?
Merck KGaA is a science and technology group from Darmstadt that operates in three areas: Life Science, Healthcare and Electronics. Life Science supplies reagents, consumables, instruments and services for research laboratories and biotech and pharmaceutical companies, including products for the manufacture of biopharmaceuticals as well as contract development and manufacturing.
The Healthcare business develops and markets prescription medicines, including in oncology, neurology and fertility. Electronics supplies specialty materials to the semiconductor and display industries. In competition, Merck is among the large global providers in the life science business alongside Thermo Fisher and Danaher. The company is broadly diversified but remains dependent in individual markets on established products and its own research pipeline. The Merck family, as owner, holds the majority of the capital and shapes the long-term direction.
Score profile
Rank vs. Drug Manufacturers - Specialty & Generic (26 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Merck KGaA ranks in the middle in the group Drug Manufacturers - Specialty & Generic (4.7/10). On growth, the company ranks below average in the group Drug Manufacturers - Specialty & Generic (2.5/10). On valuation (higher = cheaper), the stock ranks below average in the group Drug Manufacturers - Specialty & Generic (3.2/10). On financial strength, Merck KGaA ranks in the middle in the group Drug Manufacturers - Specialty & Generic (4.8/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 16.4x | 13.1x | better than 26 % |
| Trailing P/E | 33.9x | 20.5x | better than 19 % |
| PEG ratio | 2.4x | 1.6x | better than 18 % |
| EV/EBITDA | 12.0x | 12.0x | better than 50 % |
| Price/sales | 3.0x | 2.2x | better than 33 % |
| Price/book | 2.1x | 2.7x | better than 63 % |
| Revenue growth | 5.8% | 7.3% | better than 44 % |
| Earnings growth | -49.8% | 0.0% | better than 6 % |
| Gross margin | 59.0% | 63.0% | better than 40 % |
| Operating margin | 17.0% | 16.8% | better than 56 % |
| Net margin | 9.0% | 9.9% | better than 48 % |
| Return on equity | 6.4% | 7.4% | better than 44 % |
| Debt/equity | 38.1% | 84.6% | better than 75 % |
| Current ratio | 1.7x | 2.1x | better than 30 % |
| Free cash flow yield | 3.4% | 5.3% | better than 38 % |
| Dividend yield | 1.5% | 2.3% | – |
| Payout ratio | 49.8% | 31.8% | – |
| Beta | 0.81 | 0.76 | – |
Valuation: what is Merck KGaA worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Merck KGaA a model range of 100.51 EUR to 161.84 EUR per share.
14 analysts, average rating “Buy”, average price target 156.86 EUR (+4.9%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand from biotech and pharmaceutical customers for process solutions and laboratory supplies largely determines growth in the Life Science business.
- The success of medicines and the research pipeline in Healthcare influences the group's revenue and profitability.
- Investment by semiconductor and display manufacturers drives capacity utilization and revenue in Electronics.
Risks
- Patent expiries and competition from generics or biosimilars can significantly reduce revenues from established medicines.
- Setbacks in clinical trials or approvals can devalue investments in the pipeline.
- Cyclical demand in the electronics industry as well as exchange rate fluctuations weigh on earnings and predictability.
What to look for with Merck KGaA
Organic revenue growth by division is informative because it excludes currency and portfolio effects and makes the performance of the very different business areas comparable.